Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varicella zoster virus vaccine - Merck & Co

X
Drug Profile

Varicella zoster virus vaccine - Merck & Co

Alternative Names: Provarivax; V211; Varicella zoster virus vaccine live - Merck & Co; Variped; Varivax; Varivax II; Zostavax

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Osaka University
  • Developer CSL; Merck & Co; sanofi pasteur MSD
  • Class Varicella vaccines; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Herpes zoster; Varicella zoster virus infections

Most Recent Events

  • 06 Mar 2023 Registered for Varicella zoster virus infections (Prevention, In children, In adolescents, In adults) in Liechtenstein, Norway, Iceland, European Union (IM) prior to March 2023
  • 06 Mar 2023 Registered for Varicella zoster virus infections (Prevention, In children, In adults, In adolescents) in USA (IM)
  • 12 Apr 2021 Varicella zoster virus vaccine is still in phase III trials for Varicella zoster virus infection in Russia (NCT03843632)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top